This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Caisson Biotech Expands HEPtune™ Drug Delivery Deal With Novo Nordisk

OKLAHOMA CITY and AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, HEPtune , announced today that it has expanded the scope of its partnership with global healthcare leader Novo Nordisk A/S (NYSE: NVO). This latest license agreement gives Novo Nordisk 1) exclusive rights to commercialize insulin conjugated to HEPtune and 2) non-exclusive rights to leverage the HEPtune technology across other core therapeutic areas including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as Crohn's, lupus, rheumatoid and psoriatic arthritis.

Under the terms of the agreement, Caisson will be eligible to receive up to $167M in milestone payments upon achievement of certain predefined clinical, regulatory and commercial objectives plus potential long-term residual royalties.

"Novo Nordisk has completed feasibility studies that pre-clinically validate Caisson's heparosan-based drug delivery technology for product pharmacokinetics and enhanced half-life," said Dr. Paul DeAngelis, Chief Scientist of Caisson. "The HEPtune technology uses heparosan, a naturally occurring sugar polymer produced by the body that is stable and inert in the bloodstream while being biodegradable. Furthermore, HEPtune can be customized with respect to polymer size and conjugation chemistry thus providing flexibility to enhance a variety of therapeutic proteins and peptides."

"As a respected healthcare leader, Novo Nordisk has been an ideal partner and provides the infrastructure and expertise necessary to develop these much-needed therapeutic products," said Thomas Harlan, CEO of Caisson. "We look forward to our continued collaboration under this new license and to assisting Novo Nordisk in achieving its goal of developing these products and helping more patients."

About Caisson Biotech, L.L.C.

Caisson Biotech, a wholly owned subsidiary of Heparinex, L.L.C. uses novel, heparosan-based conjugates to enhance the therapeutic properties of pharmaceuticals by increasing product half-life, reducing immunogenicity, and increasing stability. Chief Scientist and Professor Dr. Paul L. DeAngelis, of the University of Oklahoma Health Sciences Center, and team developed this newly invented drug delivery platform. Visit www.caissonbiotech.com.

Caisson is funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit www.emergenttechnologies.com.

SOURCE Caisson Biotech, L.L.C.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs